Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incompleteUDCAresponse may improve outcomes
Alimentary Pharmacology & Therapeutics2015Vol. 43(2), pp. 283–293
Citations Over TimeTop 10% of 2015 papers
Angela Cheung, Lauren Lapointe‐Shaw, Matthew Kowgier, J. Meza‐Cardona, Gideon M. Hirschfield, Harry L.A. Janssen, Jordan J. Feld
Abstract
Fenofibrate therapy is associated with significant improvement in alkaline phosphatase, decompensation-free and transplant-free survival in PBC patients with incomplete UDCA response. However, fenofibrate should be used cautiously in cirrhosis, with close monitoring for clinical/biochemical decompensation. Additional studies are required to assess the validity of alkaline phosphatase as an appropriate response criteria for fibrate therapy.
Related Papers
- The effects of different fenofibrate preparation on the hyperlipidaemic rats(2003)
- Assessment of fenofibrate micronised lipanthyl 200mg therapy in hyperlipidemia(2001)
- [Ursodeoxycholic acid in primary biliary cirrhosis. 1: Therapeutic approaches up to now and the rationale for treatment with ursodeoxycholic acid].(1988)
- 저지방식이를 섭취한 난소절제 암컷 쥐에서 지질대사에 대한 fenofibrate과 17β-estradiol의 영향(2019)